interactive web-based response system (Cenduit GmbH)
90
Structured Review
Cenduit GmbH
interactive web-based response system
Interactive Web Based Response System, supplied by Cenduit GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/interactive+web-based+response+system/interactive+web+based+response+system/pmc11585249-53-5-9
Average 90 stars, based on 1 article reviews
Interactive Web Based Response System, supplied by Cenduit GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/interactive+web-based+response+system/interactive+web+based+response+system/pmc11585249-53-5-9
Average 90 stars, based on 1 article reviews
interactive web-based response system - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease Article Snippet: Patients were randomized via an Article Title: Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. Article Snippet: Published Online xxx https://doi.org/10.. 1016/j.ebiom.2023.. 104923 Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial Nicholas C. Cullen, Petr Novak,b,∗ Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, and Norbert Zilka Article Title: Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 Article Snippet: Patients were randomized via an Article Title: Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma Article Snippet: Sites should ensure that the following have been completed before randomising: • Patient consent form must be signed • Pre-randomisation evaluations should be carried out at sites as detailed in Section 5.3 (following consent if not done routinely) • The randomisation form must be fully completed prior to faxing the UCL CTC • Screening MRI scan must have been completed (a copy should be sent to UCL CTC following randomisation, see Section 7.7) On receipt of completed randomisation form at UCL CTC: • If the patient is confirmed as eligible, a patient trial number will be assigned at UCL CTC • The UCL CTC will then randomise the patient on the Article Title: Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial Article Snippet: Supply and allocation of oral drug packs was managed by an |